Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oprozomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT01832727Phase 2Terminated
- Sponsor
- Amgen
- Start
- Jul 2013
- Primary completion
- Jun 2019
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 2
01
Overview
A Phase 2 trial of oprozomib in multiple myeloma (MM), sponsored by Amgen. Started Jul 2013; status: terminated.
02
Drugs
oprozomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01832727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01832727.